乳腺癌的内分泌治疗进展__培训课件.pptVIP

* But when Ellis did the Erb B1 and 2 levels on patients, it turns out that patients who are HER-2 positive and ER positive were more likely to benefit from letrozole than they were from tamoxifen. If you were HER-2 negative and ER positive, the response rates to these 2 drugs appear equivalent, appreciating that these are fairly small numbers. So the data for superiority of one aromatase inhibitor over the other are not addressed by that question, but at least we have data that there is a unique aspect to an aromatase inhibitor in HER-2-positive disease. Whether that bears up in the other 2 a